Literature DB >> 27826366

Nucleic Acid Delivery for Endothelial Dysfunction in Cardiovascular Diseases.

Dipti Deshpande1, David R Janero1, Victor Segura-Ibarra2, Elvin Blanco2, Mansoor M Amiji3.   

Abstract

Endothelial dysfunction has been implicated in the pathophysiology of multiple cardiovascular diseases and involves components of both innate and acquired immune mechanisms. Identifying signature patterns and targets associated with endothelial dysfunction can help in the development of novel nanotherapeutic platforms for treatment of vascular diseases. This review discusses nucleic acid-based regulation of endothelial function and the different nucleic acid-based nanotherapeutic approaches designed to target endothelial dysfunction in cardiovascular disorders.

Entities:  

Keywords:  CVD; DNA damage; cardiovascular diseases; endothelium; inflammation; miRNA; nanoparticle delivery; nucleic acids; oligonucleotide-based therapeutics; oxidative stress

Mesh：

Substances：

Year:  2016        PMID： 27826366      PMCID： PMC5098569          DOI： 10.14797/mdcj-12-3-134

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN： 1947-6108


  60 in total

Review 1.  Flow, NO, and atherogenesis.

Authors:  John P Cooke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

Review 2.  Endothelial function.

Authors:  Joseph A Vita
Journal:  Circulation       Date:  2011-12-20       Impact factor: 29.690

Review 3.  Endothelial cell heterogeneity.

Authors:  William C Aird
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 4.  Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions.

Authors:  Bryan G Schwartz; Graham Jackson; Vera J Stecher; Deborah M Campoli-Richards; Robert A Kloner
Journal:  Am J Med       Date:  2013-03       Impact factor: 4.965

Review 5.  Pervasive roles of microRNAs in cardiovascular biology.

Authors:  Eric M Small; Eric N Olson
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

6.  VASCULAR INFLAMMATION AND ATHEROGENESIS ARE ACTIVATED VIA RECEPTORS FOR PAMPs AND SUPPRESSED BY REGULATORY T CELLS.

Authors:  Xiao-Feng Yang; Ying Yin; Hong Wang
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 7.  MicroRNAs as pharmacological targets in endothelial cell function and dysfunction.

Authors:  Aránzazu Chamorro-Jorganes; Elisa Araldi; Yajaira Suárez
Journal:  Pharmacol Res       Date:  2013-04-18       Impact factor: 7.658

8.  Anti-VCAM-1 and anti-E-selectin SAINT-O-Somes for selective delivery of siRNA into inflammation-activated primary endothelial cells.

Authors:  Piotr S Kowalski; Lucas L Lintermans; Henriëtte W M Morselt; Niek G J Leus; Marcel H J Ruiters; Grietje Molema; Jan A A M Kamps
Journal:  Mol Pharm       Date:  2013-07-12       Impact factor: 4.939

Review 9.  Antisense technology: an emerging platform for cardiovascular disease therapeutics.

Authors:  Richard G Lee; Jeff Crosby; Brenda F Baker; Mark J Graham; Rosanne M Crooke
Journal:  J Cardiovasc Transl Res       Date:  2013-07-16       Impact factor: 4.132

Review 10.  The vascular endothelium and human diseases.

Authors:  Peramaiyan Rajendran; Thamaraiselvan Rengarajan; Jayakumar Thangavel; Yutaka Nishigaki; Dhanapal Sakthisekaran; Gautam Sethi; Ikuo Nishigaki
Journal:  Int J Biol Sci       Date:  2013-11-09       Impact factor: 6.580
View more
  2 in total

Review 1.  Krüppel-like factors and vascular wall homeostasis.

Authors:  Yanbo Fan; Haocheng Lu; Wenying Liang; Wenting Hu; Jifeng Zhang; Y Eugene Chen
Journal:  J Mol Cell Biol       Date:  2017-10-01       Impact factor: 6.216

Review 2.  Lipid-based gene delivery to macrophage mitochondria for atherosclerosis therapy.

Authors:  Felix H Zakirov; Dongwei Zhang; Andrey V Grechko; Wei-Kai Wu; Anastasia V Poznyak; Alexander N Orekhov
Journal:  Pharmacol Res Perspect       Date:  2020-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.